急性心肌梗死患者血清促肾上腺素水平降低

Regulatory Peptides Pub Date : 2014-05-01 DOI:10.1016/j.regpep.2014.04.001

Hou-you Yu , Peng Zhao , Ming-chun Wu , Jian Liu , Wen Yin

{"title":"急性心肌梗死患者血清促肾上腺素水平降低","authors":"Hou-you Yu , Peng Zhao , Ming-chun Wu , Jian Liu , Wen Yin","doi":"10.1016/j.regpep.2014.04.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p><span>Adropin is a recently identified bioactive protein that is important for energy homeostasis and maintaining </span>insulin sensitivity<span>. We sought to detect serum adropin levels in acute myocardial infarction (AMI) patients.</span></p></div><div><h3>Methods</h3><p>We enrolled 138 AMI patients, 114 stable angina pectoris (SAP) patients and 75 controls. Adropin levels were measured by enzyme-linked immunosorbent assay (ELISA).</p></div><div><h3>Results</h3><p>Serum adropin levels were significantly lower in patients with AMI compared with SAP patients or controls (<em>P</em>  <<<0.05) in AMI patients.</p></div><div><h3>Conclusion</h3><p>Decreased serum adropin levels are associated with the presence of AMI in CAD patients. These results revealed that adropin might represent as a novel biomarker for predicting AMI onset in CAD patients.</p></div>","PeriodicalId":20853,"journal":{"name":"Regulatory Peptides","volume":"190 ","pages":"Pages 46-49"},"PeriodicalIF":0.0000,"publicationDate":"2014-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.regpep.2014.04.001","citationCount":"90","resultStr":"{\"title\":\"Serum adropin levels are decreased in patients with acute myocardial infarction\",\"authors\":\"Hou-you Yu , Peng Zhao , Ming-chun Wu , Jian Liu , Wen Yin\",\"doi\":\"10.1016/j.regpep.2014.04.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p><span>Adropin is a recently identified bioactive protein that is important for energy homeostasis and maintaining </span>insulin sensitivity<span>. We sought to detect serum adropin levels in acute myocardial infarction (AMI) patients.</span></p></div><div><h3>Methods</h3><p>We enrolled 138 AMI patients, 114 stable angina pectoris (SAP) patients and 75 controls. Adropin levels were measured by enzyme-linked immunosorbent assay (ELISA).</p></div><div><h3>Results</h3><p>Serum adropin levels were significantly lower in patients with AMI compared with SAP patients or controls (<em>P</em>  <<<0.05) in AMI patients.</p></div><div><h3>Conclusion</h3><p>Decreased serum adropin levels are associated with the presence of AMI in CAD patients. These results revealed that adropin might represent as a novel biomarker for predicting AMI onset in CAD patients.</p></div>\",\"PeriodicalId\":20853,\"journal\":{\"name\":\"Regulatory Peptides\",\"volume\":\"190 \",\"pages\":\"Pages 46-49\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.regpep.2014.04.001\",\"citationCount\":\"90\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Regulatory Peptides\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0167011514000275\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Regulatory Peptides","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0167011514000275","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 90

摘要

目的adropin是一种新发现的生物活性蛋白，在能量稳态和维持胰岛素敏感性中起重要作用。我们试图检测急性心肌梗死(AMI)患者血清促肾上腺素水平。方法纳入AMI患者138例，稳定型心绞痛(SAP)患者114例，对照组75例。采用酶联免疫吸附试验(ELISA)检测Adropin水平。结果AMI患者血清adropin水平明显低于SAP患者或对照组(P <0.01)。多因素logistic回归分析显示，低adropin是冠心病(CAD)患者AMI发生的独立预测因子(P <0.01)。血清促肾上腺素水平与体重指数(BMI)呈负相关(P <0.01)和甘油三酯水平(P <0.05)。结论冠心病患者血清adropin水平降低与AMI的发生有关。这些结果表明，adropin可能是预测冠心病患者AMI发病的一种新的生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Serum adropin levels are decreased in patients with acute myocardial infarction

Objective

Adropin is a recently identified bioactive protein that is important for energy homeostasis and maintaining insulin sensitivity. We sought to detect serum adropin levels in acute myocardial infarction (AMI) patients.

Methods

We enrolled 138 AMI patients, 114 stable angina pectoris (SAP) patients and 75 controls. Adropin levels were measured by enzyme-linked immunosorbent assay (ELISA).

Results

Serum adropin levels were significantly lower in patients with AMI compared with SAP patients or controls (P < 0.01). Multivariate logistic regression demonstrated that lower adropin was the independent predictor for the presence of AMI in coronary artery disease (CAD) patients (P < 0.01). Serum adropin levels were negatively associated with body mass index (BMI) (P < 0.01) and triglyceride levels (P < 0.05) in AMI patients.

Conclusion

Decreased serum adropin levels are associated with the presence of AMI in CAD patients. These results revealed that adropin might represent as a novel biomarker for predicting AMI onset in CAD patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Regulatory Peptides 医学-内分泌学与代谢

自引率

0.00%

发文量

审稿时长

2 months

期刊介绍： Regulatory Peptides provides a medium for the rapid publication of interdisciplinary studies on the physiology and pathology of peptides of the gut, endocrine and nervous systems which regulate cell or tissue function. Articles emphasizing these objectives may be based on either fundamental or clinical observations obtained through the disciplines of morphology, cytochemistry, biochemistry, physiology, pathology, pharmacology or psychology.